Differential sensitivity of regulatory and effector T cells to cell death: a prerequisite for transplant tolerance

Despite significant progress achieved in transplantation, immunosuppressive therapies currently used to prevent graft rejection are still endowed with severe side effects impairing their efficiency over the long term. Thus, the development of graft-specific, non toxic innovative therapeutic strategi...

Full description

Bibliographic Details
Main Author: Sylvaine eYou
Format: Article
Language:English
Published: Frontiers Media S.A. 2015-05-01
Series:Frontiers in Immunology
Subjects:
CD3
Online Access:http://journal.frontiersin.org/Journal/10.3389/fimmu.2015.00242/full
id doaj-2baa52ff6d414c0c947b70c52b568c5f
record_format Article
spelling doaj-2baa52ff6d414c0c947b70c52b568c5f2020-11-24T22:43:10ZengFrontiers Media S.A.Frontiers in Immunology1664-32242015-05-01610.3389/fimmu.2015.00242145125Differential sensitivity of regulatory and effector T cells to cell death: a prerequisite for transplant toleranceSylvaine eYou0INSERM U1151 - University Paris DescartesDespite significant progress achieved in transplantation, immunosuppressive therapies currently used to prevent graft rejection are still endowed with severe side effects impairing their efficiency over the long term. Thus, the development of graft-specific, non toxic innovative therapeutic strategies has become a major challenge, the goal being to selectively target alloreactive effector T cells while sparing CD4+Foxp3+ regulatory T cells (Tregs) to promote operational tolerance. Various approaches, notably the one based on monoclonal antibodies or fusion proteins directed against the TCR/CD3 complex, TCR coreceptors, or costimulatory molecules, have been proposed to reduce the alloreactive T cell pool which is an essential prerequisite to create a therapeutic window allowing Tregs to induce and maintain allograft tolerance. In this minireview, we focus on the differential sensitivity of Tregs and effector T cells to the depleting and inhibitory effect of these immunotherapies, with a particular emphasis on CD3-specific antibodies that beyond their immunosuppressive effect, also express potent tolerogenic capacities.http://journal.frontiersin.org/Journal/10.3389/fimmu.2015.00242/fullImmunotherapytolerancemonoclonal antibodiesCD3depletionFoxp3+ Tregs
collection DOAJ
language English
format Article
sources DOAJ
author Sylvaine eYou
spellingShingle Sylvaine eYou
Differential sensitivity of regulatory and effector T cells to cell death: a prerequisite for transplant tolerance
Frontiers in Immunology
Immunotherapy
tolerance
monoclonal antibodies
CD3
depletion
Foxp3+ Tregs
author_facet Sylvaine eYou
author_sort Sylvaine eYou
title Differential sensitivity of regulatory and effector T cells to cell death: a prerequisite for transplant tolerance
title_short Differential sensitivity of regulatory and effector T cells to cell death: a prerequisite for transplant tolerance
title_full Differential sensitivity of regulatory and effector T cells to cell death: a prerequisite for transplant tolerance
title_fullStr Differential sensitivity of regulatory and effector T cells to cell death: a prerequisite for transplant tolerance
title_full_unstemmed Differential sensitivity of regulatory and effector T cells to cell death: a prerequisite for transplant tolerance
title_sort differential sensitivity of regulatory and effector t cells to cell death: a prerequisite for transplant tolerance
publisher Frontiers Media S.A.
series Frontiers in Immunology
issn 1664-3224
publishDate 2015-05-01
description Despite significant progress achieved in transplantation, immunosuppressive therapies currently used to prevent graft rejection are still endowed with severe side effects impairing their efficiency over the long term. Thus, the development of graft-specific, non toxic innovative therapeutic strategies has become a major challenge, the goal being to selectively target alloreactive effector T cells while sparing CD4+Foxp3+ regulatory T cells (Tregs) to promote operational tolerance. Various approaches, notably the one based on monoclonal antibodies or fusion proteins directed against the TCR/CD3 complex, TCR coreceptors, or costimulatory molecules, have been proposed to reduce the alloreactive T cell pool which is an essential prerequisite to create a therapeutic window allowing Tregs to induce and maintain allograft tolerance. In this minireview, we focus on the differential sensitivity of Tregs and effector T cells to the depleting and inhibitory effect of these immunotherapies, with a particular emphasis on CD3-specific antibodies that beyond their immunosuppressive effect, also express potent tolerogenic capacities.
topic Immunotherapy
tolerance
monoclonal antibodies
CD3
depletion
Foxp3+ Tregs
url http://journal.frontiersin.org/Journal/10.3389/fimmu.2015.00242/full
work_keys_str_mv AT sylvaineeyou differentialsensitivityofregulatoryandeffectortcellstocelldeathaprerequisitefortransplanttolerance
_version_ 1725697158038945792